"目录号: HY-13700
Nedaplatin是顺铂衍生物和DNA损伤剂。
相关产品
Cycloheximide-Actinomycin D-Mitomycin C-Gemcitabine-SCR7-alpha-Amanitin-Streptozocin-Capecitabine-Bleomycin sulfate-CX-5461-Hydroxyurea-Triciribine-LMI070-COH29-TH588-
生物活性
Description
Nedaplatin is a derivative of cisplatin and DNA damage agent.Target: OthersNedaplatin(NDP) is a derivative of cisplatin which produced less nausea & vomiting and nephrotoxicity. the effect of NDP on the 7-ethyl-1-hydroxy-CPT (the active form of CPT-11)-induced inhibitory effect on DNA topoisomerase I was examined. The topoisomerase I-inhibitory effect of 7-ethyl-1-hydroxy-CPT was enhanced 10-fold in the presence of NDP at microgram/milliliter concentrations [1]. NDP was developed as a second generation platinum complex. Because it has greater antitumour activity and lower nephrotoxicity than cisplatin (CDDP). At the high-dose of NDP in FN therapy, a reduction of tumour size and long-term tumour-free survival were frequently observed. The survival effect of the combinations of NDP with 5-FU was superior to those of the combination of CDDP with 5-FU. In conclusion, the sequence-dependent antitumour efficacy and toxicity of the combination of NDP or CDDP with 5-FU was demonstrated in this study, and FN therapy appeared to be the most efficient regimen as a clinical therapy [2].
Clinical Trial
Zhejiang Cancer Hospital
Esophageal Cancer
January 2010
Phase 1
Yuhong Li-Sun Yat-sen University
Esophageal Squamous Cell Carcinoma
January 2015
Phase 2
Chinese Academy of Medical Sciences
Uterine Cervical Cancer
November 2011
Phase 2
Sun Yat-sen University
Esophageal Carcinoma
January 2010
Phase 2
He Xia-Jiangsu Cancer Institute & Hospital
Nasopharyngeal Carcinoma
December 2014
Phase 3
Sun Yat-sen University-Guangzhou Medical University-The First Affiliated Hospital of Guangdong Pharmaceutical University-Meizhou City Hospital Of Guangdong Provience
Nasopharyngeal Carcinoma
February 2012
Phase 3
Guangdong Association of Clinical Trials
Non-Small Cell Lung Cancer
October 2015
Phase 3
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Nasopharyngeal Carcinoma
January 2011
Phase 2
Jiangsu Simcere Pharmaceutical Co., Ltd.
Squamous Cell Carcinoma
December 2013
Phase 4
Guangxi Medical University-People's Hospital of Guangxi-303rd Hospital of the People's Liberation Army-Nanning Second People's Hospital-Guangxi Traditional Chinese Medical University-Guilin Medical College-Guangxi Naxishan Hospital-Liuzhou Worker's Hospital-Liuzhou People's Hospital-Liuzhou Hospital of Traditional Chinese Medicine-Liuzhou Cancer Hospital-Liuzhou Railway hospital-First People's Hospital of Yulin-The Red Cross hospital of YuLin-Guigang People's Hospital-The Red Cross hospital of Wuzhou
Nasopharyngeal Carcinoma
November 2011
Phase 3
Sun Yat-sen University
Esophageal Squamous Cell Carcinoma
November 2016
Phase 1
Sun Yat-sen University
Recurrent and Metastatic Nasopharyngeal Carcinoma
June 2016
Phase 2
Yun-fei Xia-Jiangsu Simcere Pharmaceutical Co., Ltd.-Sun Yat-sen University
Nasopharyngeal Carcinoma
July 2015
Phase 2
Rongjie Tao-National Natural Science Foundation of China-Shandong Cancer Hospital and Institute
Central Nervous System Tumors
June 2008
Phase 2
Changjie Huang-Nanning Second People's Hospital
Nasopharyngeal Carcinoma
January 2014
Phase 3
Third Military Medical University
Non-small Cell Lung Cancer
January 2010
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Cervical Cancer-Complications
November 2012
Phase 2
Jiangsu Cancer Institute & Hospital
Nasopharyngeal Carcinoma
September 2012
Phase 2
Jiangsu Cancer Institute & Hospital
Nasopharyngeal Carcinoma
May 2010
Phase 1-Phase 2
Chinese Academy of Medical Sciences
Esophageal Neoplasms
January 2015
Phase 1-Phase 2
Chinese Academy of Medical Sciences
Esophagus Cancer-Esophagogastric Junction Cancer
October 2016
Shanghai University of Traditional Chinese Medicine-Shanghai Chest Hospital-Shanghai Pulmonary Hospital, Shanghai, China
Cancer
September 2014
Phase 2-Phase 3
Chinese Academy of Medical Sciences-Hebei Medical University Fourth Hospital-Affiliated Hospital of Hebei University-Beijing Army General Hospital-Beijing Hospital-Peking University First Hospital-Tianjin Medical University Cancer Institute and Hospital-Henan Cancer Hospital-The Affiliated Hospital of Inner Mongolia Medical University-The First Affiliated Hospital with Nanjing Medical University-Fujian Cancer Hospital
Esophageal Neoplasms
June 2016
Phase 2
Zefen Xiao-Chinese Academy of Medical Sciences
Esophageal Neoplasms-Esophageal Cancer
October 2014
Phase 2-Phase 3
View MoreCollapse
References
